CClinicalTrials.gg
CompletedNCT02676297Updated Dec 2, 2024

Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products

A Phase 1 interventional study of tiotropium in Healthy, sponsored by Solventum US LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Solventum US LLC · Phase 1, Interventional, and Basic science

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the absorption of two different inhalation products with the reference product in healthy volunteers.

Read the detailed description

Healthy subjects will be enrolled and will receive single doses of 2 test inhalation products and one reference inhalation product according to a three-period cross-over design. Subjects will use the patient instruction leaflet to understand how each inhaler is administered. Plasma tiotropium levels will be measured pre-dose and over 8 hours post-dose.

02

Conditions studied

  • Healthy

Keywords

  • inhalation
  • anticholinergic
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 62 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy Volunteer
  • Willing and able to give informed consent
  • Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
  • Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders
  • Any presence or history of a clinically significant allergy including any adverse reaction to study drug
  • History of drug or alcohol abuse within the past 2 years
  • Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)
  • Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
  • Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
  • If female, nursing, lactating or pregnant
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Test product A

    tiotropium

    Drug: tiotropium

  • Experimental
    Test product B

    tiotropium

    Drug: tiotropium

  • Active comparator
    reference product

    tiotropium

    Drug: tiotropium

Interventions

  • Drugtiotropium

    four inhalations

    Also known as: Spiriva Respimat

06

What researchers measure

Primary outcomes

  1. peak plasma concentration

    measured by noncompartmental analysis

    Time frame: 8 hours

Secondary outcomes

  1. adverse events

    reported adverse events

    Time frame: 8 hours

Other outcomes

  1. area under the plasma concentration vs. time curve

    measured by the trapezoidal rule

    Time frame: 8 hours

07

Study locations

1 site
  • Quotient Clinical Ltd
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — will share summary data

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02676297
Lead sponsor
Solventum US LLC
Collaborators
Quotient Clinical, 3M
Responsible party
Sponsor
First posted
Feb 8, 2016
Start date
Jan 2016
Primary completion
May 2016
Completion
Jul 2016
Last update
Dec 2, 2024

Study contacts

Pui Leung, MD
principal investigator · Quotient Clinical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion